Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPIRESCUE: Nivolumab + Ipilimumab in resistant MSI/dMMR mCRC
NCT05310643Phase 2Recruiting
- Sponsor
- GERCOR
- Start
- May 2022
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in colorectal cancer (CRC), sponsored by GERCOR. Started May 2022; status: recruiting.
02
Drugs
ipilimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05310643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05310643.